Vanguard disaggregates holdings after realignment (VYGR) — reports 0% ownership
Rhea-AI Filing Summary
Voyager Therapeutics Inc Schedule 13G/A amendment shows The Vanguard Group reports 0% beneficial ownership of Voyager common stock, with 0 shares reported. The filing notes an internal realignment on January 12, 2026, after which certain Vanguard subsidiaries report disaggregated ownership separately in reliance on SEC Release No. 34-39538. The amendment is signed by Ashley Grim on 03/27/2026.
Positive
- None.
Negative
- None.
Insights
Routine amendment records disaggregation; holdings reported as zero.
The amendment updates beneficial ownership reporting for The Vanguard Group, showing 0 shares and 0% of Voyager Therapeutics common stock. It cites the internal realignment effective January 12, 2026 and reliance on SEC Release No. 34-39538 for separate subsidiary reporting.
Cash‑flow treatment and any trading activity are not stated in the excerpt; subsequent filings would show changes if holdings arise.
Disaggregation reflects internal structuring, not an ownership increase or sale.
The filing describes that subsidiaries or business divisions will report beneficial ownership separately from The Vanguard Group in reliance on the cited SEC release. The statement emphasizes these entities "pursue the same investment strategies" as pre‑realignment.
Investors should note this is an administrative reporting change; the amendment documents current beneficial ownership as 0 shares and 0%.
AI-generated analysis. How Rhea-AI works. Not financial advice.